146 related articles for article (PubMed ID: 28138829)
21. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and excretion of
van Andel L; Fudio S; Rosing H; Munt S; Miguel-Lillo B; González I; Tibben MM; de Vries N; de Vries Schultink AHM; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Oct; 35(5):589-598. PubMed ID: 28111728
[TBL] [Abstract][Full Text] [Related]
24. Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
Advani RH; Hurwitz HI; Gordon MS; Ebbinghaus SW; Mendelson DS; Wakelee HA; Hoch U; Silverman JA; Havrilla NA; Berman CJ; Fox JA; Allen RS; Adelman DC
Clin Cancer Res; 2010 Apr; 16(7):2167-75. PubMed ID: 20233886
[TBL] [Abstract][Full Text] [Related]
25. Excretion and metabolism of trovafloxacin in humans.
Dalvie DK; Khosla N; Vincent J
Drug Metab Dispos; 1997 Apr; 25(4):423-7. PubMed ID: 9107540
[TBL] [Abstract][Full Text] [Related]
26. Biotransformation and mass balance of faldaprevir, a hepatitis C NS3/NS4 protease inhibitor in rats.
Chen L; George RS; Norris SH; Mao Y; Philip E; Wang LQ; Wu D; Potchoiba MJ
Xenobiotica; 2014 Nov; 44(11):1014-25. PubMed ID: 24831541
[TBL] [Abstract][Full Text] [Related]
27. Excretion mass balance evaluation, metabolite profile analysis and metabolite identification in plasma and excreta after oral administration of [14C]-meloxicam to the male cat: preliminary study.
Grudé P; Guittard J; Garcia C; Daoulas I; Thoulon F; Ebner T
J Vet Pharmacol Ther; 2010 Aug; 33(4):396-407. PubMed ID: 20646203
[TBL] [Abstract][Full Text] [Related]
28. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C- and 3H-labeled ziprasidone.
Prakash C; Kamel A; Anderson W; Howard H
Drug Metab Dispos; 1997 Feb; 25(2):206-18. PubMed ID: 9029052
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy.
Dubbelman AC; Rosing H; Darwish M; D'Andrea D; Bond M; Hellriegel E; Robertson P; Beijnen JH; Schellens JH
Drugs R D; 2013 Mar; 13(1):17-28. PubMed ID: 23322528
[TBL] [Abstract][Full Text] [Related]
31. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
[TBL] [Abstract][Full Text] [Related]
32. Metabolism and excretion of trovafloxacin, a new quinolone antibiotic, in Sprague-Dawley rats and beagle dogs. Effect of bile duct cannulation on excretion pathways.
Dalvie DK; Khosla NB; Navetta KA; Brighty KE
Drug Metab Dispos; 1996 Nov; 24(11):1231-40. PubMed ID: 8937858
[TBL] [Abstract][Full Text] [Related]
33. Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans.
Kochansky CJ; Rippley RK; Yan KX; Song H; Wallace MA; Dean D; Jones AN; Lasseter K; Schwartz J; Vincent SH; Franklin RB; Wagner J
Drug Metab Dispos; 2006 Sep; 34(9):1457-61. PubMed ID: 16772365
[TBL] [Abstract][Full Text] [Related]
34. Metabolite profiles and mass balance of fuzuloparib, a novel poly (ADP-ribose) polymerase inhibitor, in subjects with advanced solid cancers.
Bian Y; Meng J; Ma S; Li G; Wang Y; Li S; Liu L; Huang C; Zhang H; Zhong D; Miao L
Br J Clin Pharmacol; 2022 Jul; 88(7):3307-3320. PubMed ID: 35112382
[TBL] [Abstract][Full Text] [Related]
35. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
36. Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.
Dymond AW; Howes C; Pattison C; So K; Mariani G; Savage M; Mair S; Ford G; Martin P
Clin Ther; 2016 Nov; 38(11):2447-2458. PubMed ID: 27751676
[TBL] [Abstract][Full Text] [Related]
37. Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers.
Morris CA; Dueker SR; Lohstroh PN; Wang LQ; Fang XP; Jung D; Lopez-Lazaro L; Baker M; Duparc S; Borghini-Fuhrer I; Pokorny R; Shin JS; Fleckenstein L
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):75-86. PubMed ID: 24590312
[TBL] [Abstract][Full Text] [Related]
38. Vosaroxin : a novel antineoplastic quinolone.
Abbas JA; Stuart RK
Expert Opin Investig Drugs; 2012 Aug; 21(8):1223-33. PubMed ID: 22724917
[TBL] [Abstract][Full Text] [Related]
39. Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans.
Weinz C; Schwarz T; Kubitza D; Mueck W; Lang D
Drug Metab Dispos; 2009 May; 37(5):1056-64. PubMed ID: 19196845
[TBL] [Abstract][Full Text] [Related]
40. A Phase I, Open-Label, Mass Balance Study of [
Cheng Y; Wang X; Liu L; Silva J; Thomas M; Li Y
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):355-365. PubMed ID: 38521893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
